Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Lipocine Reports Topline Results From Phase 2 Proof-Of-Concept Study of LPCN 1148 in Liver Cirrhosis
 Thursday, July 27, 2023
 8:30am EDT